GlassScriptPhysician profile
Frank J Monte
NPI 1346355021
$1,369.75
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.34 · 2021: $29.09 · 2022: $378 · 2023: $597 · 2024: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $196.60 | 2022-2024 | |
| Abbvie INC. | $193.65 | 2021-2024 | |
| Lilly USA, LLC | $138.46 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $113.48 | 2022-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $113.23 | 2022-2023 | |
| Glaxosmithkline, LLC. | $93.45 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $75.39 | 2022-2023 | Prolia, Evenity, Repatha |
| Exact Sciences Corporation | $66.51 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $64.90 | 2022-2023 | Leqvio |
| Biohaven Pharmaceutical Holding Company LTD. | $58.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.03 | 2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $40.97 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $26.41 | 2019-2023 | Belsomra |
| Abbott Laboratories | $23.09 | 2023 | Freestyle Libre |
| Alexion Pharmaceuticals, INC. | $21.10 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2022 | |
| Boston Scientific Corporation | $15.87 | 2022 | |
| Dexcom, INC. | $15.29 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $14.60 | 2019 | |
| Amarin Pharma, INC. | $14.52 | 2019 | |
| Forte Bio-Pharma LLC | $13.45 | 2023 | Prolate, Nalocet |
| Sumitomo Pharma America, INC. | $11.65 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Monte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.